LEVERKUSEN, Germany (AFX) - Bayer Pharmaceuticals Corp and Onyx Pharmaceuticals Inc announced that Bayer has submitted an application for EU approval of their sorafenib cancer treatment to the European Medicines Agency (EMEA) in London.
Sorafenib is used to treat kidney cancer. It is being jointly developed by Bayer and Onyx.
The companies also announced a Phase III trial of this drug in the EU for patients with advanced kidney cancer. The study, will take place at sites in 11 countries including Germany, France, UK, Spain, Italy, the Netherlands and Poland.
amk/jfr
COPYRIGHT
Copyright AFX News Limited 2005. All rights reserved.
The copying, republication or redistribution of AFX News content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and the AFX Financial News logo are registered trademarks of AFX News Limited
For more information and to contact AFX: www.afxnews.com and www.afxpress.com
Sorafenib is used to treat kidney cancer. It is being jointly developed by Bayer and Onyx.
The companies also announced a Phase III trial of this drug in the EU for patients with advanced kidney cancer. The study, will take place at sites in 11 countries including Germany, France, UK, Spain, Italy, the Netherlands and Poland.
amk/jfr
COPYRIGHT
Copyright AFX News Limited 2005. All rights reserved.
The copying, republication or redistribution of AFX News content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and the AFX Financial News logo are registered trademarks of AFX News Limited
For more information and to contact AFX: www.afxnews.com and www.afxpress.com
© 2005 AFX News
